Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates
08:41am, Tuesday, 28'th Oct 2025
Regeneron (REGN) came out with quarterly earnings of $11.83 per share, beating the Zacks Consensus Estimate of $9.44 per share. This compares to earnings of $12.46 per share a year ago.
Regeneron beats quarterly estimates on strong demand for Dupixent
07:30am, Tuesday, 28'th Oct 2025
Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending its shares
Regeneron Reports Third Quarter 2025 Financial and Operating Results
06:30am, Tuesday, 28'th Oct 2025
TARRYTOWN, N.Y., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2025 and provided a business update.
Has Regeneron Stock Quietly Become A Value Buy?
08:35am, Monday, 27'th Oct 2025
Here is why we believe Regeneron Pharmaceuticals (REGN) stock is worthy of consideration as a value investment. It is presently trading nearly 38% lower than its one-year peak, and is also being trade
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
11:02am, Friday, 24'th Oct 2025
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning
04:30am, Friday, 24'th Oct 2025
We purchased several new fund holdings across various sectors. Sempra has been shifting its strategic focus from its highly regulated California operations to its growing presence in Texas. Regeneron
7 Stocks Taking The Next Step To Be On Offense
07:30pm, Thursday, 23'rd Oct 2025
Bio-Rad Laboratories was a positive contributor after the company reported steadier earnings than the market expected. PVH also remains our largest share repurchaser for the year after buying a teens
Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS
10:16am, Thursday, 23'rd Oct 2025
Evaluate the expected performance of Regeneron (REGN) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metr
Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline
11:06am, Tuesday, 21'st Oct 2025
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
03:56am, Thursday, 16'th Oct 2025
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma New s
2 Stocks Down 17% and 21% to Buy Right Now
10:00am, Tuesday, 14'th Oct 2025
One way to earn above-average market returns -- which isn't always easy -- is to invest in companies that have lagged the market but are likely to recover over the long run. As the basic investing max
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
11:06am, Monday, 13'th Oct 2025
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued improv
